Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results add to the evidence that IL10 plays a role in multiple sclerosis and suggest that decreased production of this interleukin allows the proliferation of autoreactive T cells at the onset of the disease.
|
9068068 |
1996 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We used semiquantitative polymerase chain reaction (RT-PCR) to measure mRNA levels for cytokines before and after IFN beta-1b therapy. mRNA was extracted from mononuclear cells of nine healthy controls and 31 patients with MS. Before therapy, IL-10 and leukemia inhibitory factor (LIF) mRNA levels were elevated in stable MS compared to active MS. Twenty four hours after IFN beta-1b treatment, mRNA levels for IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IFN-gamma, TNF-alpha and LIF had not changed.
|
9345428 |
1996 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IFN-gamma and IL-10 mRNA levels were higher in MS patients than in other inflammatory neurological diseases.
|
9413269 |
1997 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse.
|
9630160 |
1998 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis.
|
10360761 |
1999 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The expression of tumor necrosis factor-alpha, interleukin-10 (IL-10) and IL-12 mRNA in CSF MNC did not differ between MS patients with and without active MRI lesions.
|
10416508 |
1999 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IL10 polymorphism does not appear to be associated with MS or to influence disease progression.
|
10580805 |
1999 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analysed this diallelic polymorphism in patients with multiple sclerosis but did not find any association between a certain -1082 IL10 genotype and susceptibility to or severity of multiple sclerosis.
|
10683520 |
2000 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Long-term effect of IFNbeta1b treatment on the spontaneous and induced expression of IL-10 and TGFbeta1 in MS patients.
|
11054484 |
2000 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, innate IL-10- and interferon (IFN)-gamma-secreting T cells responsive to TCR peptides were quantified in peripheral blood mononuclear cells of MS patients and healthy controls (HC) using the ELISPOT assay.
|
11592112 |
2001 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-10 (IL-10) secretion affects the inducibility of experimental autoimmune encephalomyelitis and the outcome of multiple sclerosis (MS).
|
12039409 |
2002 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to determine whether sequence variations in the IL-10 gene were associated with MS susceptibility and progression.
|
12101075 |
2003 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
The aim of our study was to determine whether sequence variations in the IL-10 gene were associated with MS susceptibility and progression.
|
12101075 |
2003 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we discuss the role of IL-10 in autoimmune diseases and examine its beneficial effects in cellular-based autoimmune diseases such as multiple sclerosis (MS) or its involvement in humoral-based autoimmune diseases such as systemic lupus erythematosus (SLE).
|
12220553 |
2003 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS).
|
12220553 |
2003 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The primary progressive MS patients with the low IL-10 expression haplotype showed a trend towards a worse clinical outcome than did patients with medium- or high-expression haplotypes (P = 0.056).
|
12220699 |
2002 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The data indicate that IL-10 is not a major susceptibility locus in MS, but in our population it might, however, have a minor role.
|
12458048 |
2002 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that differential production of IL-10 might be a factor in the severity of MS.
|
14616291 |
2003 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results prove a minor role of IL-10 in the autoimmune diabetes risk, although we found the same association trend with IL-10G(*)12 allele as was previously observed for multiple sclerosis and rheumatoid arthritis.
|
15057267 |
2004 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis.
|
15693804 |
2005 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis.
|
15693804 |
2005 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the size of the study group is small, these results indicate that polymorphic variations of two of the major anti-inflammatory cytokines, IL-10 and TGF-beta, may play a role in MS susceptibility.
|
16183136 |
2005 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
There were striking defects in the induction of Tr1 cells with CD46 costimulation as measured by IL-10 but not IFN-gamma secretion in patients with MS compared with healthy subjects.
|
17099776 |
2006 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution.
|
17481737 |
2007 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
These results indicate that IL-10 regulatory function is impaired in patients with MS.
|
18200504 |
2008 |